Health Discovery Corporation Offers an Intra-Quarterly Update, Commentary on the Value of Prostate Cancer Screening and Invites the American Cancer Society to Act Immediately

SAVANNAH, Ga.--(Business Wire)--
Due to the recent downward pressure on the price of Health Discovery
Corporation`s common stock (OTCBB: HDVY) after breaking through multiple 52-week
highs in a few short weeks as it did in the past month, the Company has received
numerous investor inquiries. Given these inquiries and in order to make Company
information available on a uniform basis, the Company would like to provide an
intra-quarterly update on its activities, to and including, but not limited to,
the following since its most recent quarterly filing:

* The Company`s private placement Series B fund raising is going extremely well
and the Company expects to close this round of financing in the next few weeks.
These Series B shares are not common shares and are not registered with the
Securities and Exchange Commission. We are pleased to announce that many of the
participants in this Series B funding round are current shareholders of the
Company.
* The Company continues to make great progress on its urine-based prostate
cancer test.

As previously announced, HDC recently entered into royalty-bearing licenses for
its new urine-based prostate cancer test with Quest Diagnostics Incorporated
(NYSE: DGX)and Abbott Laboratories (NYSE: ABT) for development and
commercialization. The Company also entered into royalty-bearing licenses for
its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE:
ABT) and Clarient Inc. (NasdaqCM: CLRT)for development and commercialization.

* The Company`s minority-owned subsidiary, Smart Personalized Medicine, LLC, has
recently entered into a licensing agreement with a world-renowned international
cancer center to develop a breast cancer prognostic test and, with the Company,
are currently in discussions with a national clinical laboratory for development
and commercialization of the test.
* The Company is finalizing the image processing development on its PAP Smear
interpretation test. The Company entered into a development and
commercialization agreement with DCL Laboratories for this test as well as tests
for ovarian and endometrial cancer.
* Discussions are underway with an international diagnostics company regarding
the development and commercialization of the Company`s colon cancer molecular
diagnostic test.
* Since the recent press release on the status of the Company`s IP portfolio on
October 19, 2009, the United States Patent and Trademark Office has issued
additional Notices of Allowance on two of HDC`s patent applications covering the
use of SVMs for analysis of spectral data. Spectral data are generated by
instruments including mass spectrometers, which are widely used for detection of
chemical properties of materials that can be analyzed based on their atomic or
molecular weights, optical detectors, such as infrared telescopes and laser
analyzers, audio signal analyzers, and medical testing systems, such as EEG and
ECG analysis. Both patent applications cover the direct analysis of spectral
data using SVMs, which represents a significant improvement over earlier methods
that required identification and extraction of individual peaks in the spectra,
which was frequently a manual operation, before any analysis could occur.

"As a Company, we are focused on creating shareholder value and expect that from
time to time shareholders will take some profits from their investment,
especially when the company breaks through multiple 52-week highs in a few short
weeks as we did in the past month," Dr. Barnhill said. "Additionally, we were
proud to be recently listed by the Wall Street Journal Market Watch as a "Best
Performing Stock" in the Biotechnology sector.

"Over the past several months, the Company has taken prudent, definitive steps
to strengthen its staffing, to bolster its investor relations/public relations
capacity by hiring a New York City firm and to improve our capital structure,"
said Dr. Barnhill.

"I am very excited by our progress and feel that there has never been a more
promising time in the Company`s history than now," said Dr. Barnhill.

Prostate Cancer Screening Remains Vitally Important

There appears to be considerable confusion in the media regarding the American
Cancer Society`s position on the value of universal prostate cancer screening.
The critical issue regarding the American Cancer Society`s position on prostate
cancer screening is not that screening, per se, is unwarranted but that the
currently available PSA diagnostic test is inadequate for justifying mass
screening for prostate cancer, and that a new, more accurate test is desperately
needed. In other words, it is the test, not the testing, that is inadequate,
wasteful, and in some cases, harmful, and given the availability of the "right"
test, it would be unwise to abandon prostate cancer screening or even seriously
consider doing so.

U.S. & Global Market Opportunity for Health Discovery Corporation

HDC receives, licensing and milestones fees as well as royalty payments on a per
test basis upon the sale of patient tests, including HDC`s prostate cancer
tests. HDC`s initial target market for prostate cancer is significant. For
example, in the U.S. alone there are 25 million PSA tests (prostate specific
antigen) performed annually. There are an additional 25 million PSA tests
performed annually outside the U.S. The PSA test sells in U.S. national clinical
laboratories for approximately $100 per test. The PSA test has come under
increasing scrutiny due to its known limitations. HDC, with its partners,
expects to provide an alternative to the PSA test in the U.S. and globally.

According to Dr. Barnhill, "The future for cancer screening is indeed bright."
In fact, it would be impossible to accomplish the nation`s best visions for
healthcare-reform without vastly increasing the numbers of patients being
screened and the frequency of their early-detection screenings-as well as
increasing the use of companion diagnostic tests to screen for those patients
who are likely to respond favorably to an expensive or dangerous therapy, such
as chemotherapy.

Health Discovery Corporations Invites the American Cancer Society to Act
Immediately

Given the promising future of molecular diagnostic testing, and the increased
accuracy of these tests, Health Discovery Corporation asks that the American
Cancer Society immediately and strongly reassert its position that, at least, in
the case of prostate cancer screening, the availability of a new and vastly
superior screening diagnostic tool could be of immense public health benefit.

If we focus on the science, as well as the economics, because, as it turns out
both are in alignment here, we will jointly get to the right place after all, a
place where the benefits of prostate cancer screening using a new, very powerful
test far outweigh the risks and other costs.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses
advanced mathematical techniques to analyze large amounts of data to uncover
patterns that might otherwise be undetectable. It operates primarily in the
emerging field of personalized medicine where such tools are critical to
scientific discovery. Its primary business consists of licensing its
intellectual property and developing its own product line of biomarker-based
diagnostic tests that include human genes and genetic variations, as well as
gene, protein, and metabolic expression differences and image analysis in
digital pathology and radiology. For more information, see
www.healthdiscoverycorp.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, the accuracy of which is
necessarily subject to risks and uncertainties, including, without limitation,
statements regarding future performance, opportunities and investments, and
anticipated results in general. From time to time the Company may make other
forward-looking statements relating to other matters, including without
limitation, commercialization plans and strategic partnerships. Actual results
may differ materially due to a variety of factors, including, among other
things, the acceptance of our approach to applying mathematics computer science
and physics into the disciplines of biology, organic chemistry and medicine and
our products and technologies associated with those approaches, the ability to
develop or commercialize new drugs, therapies or other products based on our
approaches, and other factors set forth from time to time in the Company`s
Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this
document are made as of the date hereof based on information available to the
Company as of the date hereof, and the Company assumes no obligation to update
any forward-looking statement or cautionary statement.

for Health Discovery Corporation
Tom Gallagher, 212-922-0900
Investor Relations
tgallagher@dgi-nyc.com
or
Matthew Swetonic, 212-922-0900
Media Relations
mswetonic@dgi-nyc.com

Copyright Business Wire 2009